The US lacks the capacity to treat long COVID, and HHS defunding is taking the country further away from being able to handle the country’s growing number of long COVID cases.
- Professor of Health Policy and Management, City University of New York
Once a coronavirus vaccine is approved, billions of doses need to be manufactured. Current vaccine production is nowhere near ready, for a variety of reasons, but planning now could help.
Una vacuna con un 70% de efectividad podría no ser lo suficientemente eficaz si muy pocas personas están dispuestas a ser vacunadas, según muestran las nuevas investigaciones.
A vaccine that’s 70% effective might not be good enough if too few people are willing to be vaccinated, new research shows.
Reopening state economies too soon risks a second wave of the pandemic, and a surge in medical costs. Anyone who pays insurance premiums and taxes will be picking up the tab.
Contact Bruce for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Location: New York, New York, U.S.
- Website
- BlueSky: @bruceylee.bsky.social
- Instagram: bruce_y_lee
- LinkedIn: bruce-y-lee-68a6834/
- X (formerly Twitter): @bruce_y_lee
- Article Feed
- Joined




